pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

5,475 catalysts · 5,159 phase readout · 2,355 8k filing · 316 pdufa · 275 earnings · 108 phase 2 completion · 50 phase 1 completion

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-07-27: 0 catalysts2026-07-28: 0 catalysts2026-07-29: 60 catalysts2026-07-30: 13 catalysts2026-07-31: 3 catalysts2026-08-01: 0 catalysts2026-08-02: 0 catalysts2026-08-03: 4 catalysts2026-08-04: 12 catalysts2026-08-05: 14 catalysts2026-08-06: 10 catalysts2026-08-07: 1 catalyst2026-08-08: 0 catalysts2026-08-09: 0 catalysts2026-08-10: 1 catalyst2026-08-11: 1 catalyst2026-08-12: 1 catalyst2026-08-13: 0 catalysts2026-08-14: 0 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 0 catalysts2026-08-18: 1 catalyst2026-08-19: 0 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 0 catalysts2026-08-27: 0 catalysts2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 0 catalysts2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 0 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 0 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 0 catalysts2026-10-14: 0 catalysts2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 0 catalysts2026-10-20: 1 catalyst2026-10-21: 0 catalysts2026-10-22: 2 catalysts2026-10-23: 0 catalysts2026-10-24: 0 catalysts2026-10-25: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type: pdufa×type: phase readout×type: grant×clear all
type
  • phase readout5,159
  • 8k filing2,355
  • pdufa316
  • earnings275
  • phase 2 completion108
  • phase 1 completion50
phase 1 2 completion
28
  • phase 1 initiation22
  • phase 0 trial completion21
  • phase 1 2 initiation9
  • therapy area

    no tagged catalysts yet

    Date TBD

    50
    ›COMPLETEDphase readoutNCT05228470: A Study of Elranatamab (PF-06863135) in Chinese Participants With Refractory Multiple Myeloma.

    Sponsor: Pfizer. Phase: PHASE2. Conditions: Elranatamab, Myeloma, Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma, PF-06863135, BCMA, Bispecific, Bispecific Antibody, BCMA-CD3 Bispecific, MagnetisMM-8

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05748873: Promising ROd-cone DYstrophy Gene therapY

    Sponsor: SparingVision. Phase: PHASE1. Conditions: Retinitis Pigmentosa

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05471973: CIED Infection Quality Initiative Demonstration Project

    Sponsor: Duke University. Phase: NA. Conditions: Infections

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT03364569: Usefullness of Peri-operative Tranexamic Acid in Primary Breast Augmentation With Implants.

    Sponsor: Hôpital NOVO. Phase: . Conditions: Plastic Surgery

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05819541: Treating Exacerbations of Asthma With Oral Montelukast in Children

    Sponsor: Vanderbilt University Medical Center. Phase: PHASE2. Conditions: Status Asthmaticus

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05228041: BIOlogics in Severe Nasal POlyposis SurvEy

    Sponsor: University Hospital, Lille. Phase: . Conditions: Chronic Rhinosinusitis With Nasal Polyps

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05515341: A DirEct to PatieNt Study in Chronic Pain

    Sponsor: Boston Scientific Corporation. Phase: . Conditions: Chronic Pain

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07512154: Precision Radiotherapy Enabled by Molecular MRI

    Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Phase: NA. Conditions: Brain Cancer

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06273605: The Egg Up Trial - Testing a New Treatment Pathway for Infants With Newly Diagnosed Egg Allergy

    Sponsor: Murdoch Childrens Research Institute. Phase: NA. Conditions: Food Allergy, Food Allergy in Infants

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05346354: Efficacy and Safety Study of Ravulizumab IV in Pediatric Participants With NMOSD

    Sponsor: Alexion Pharmaceuticals, Inc.. Phase: PHASE2. Conditions: Neuromyelitis Optica Spectrum Disorder

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT05351905: Improving Pain Disability With the Use of Oral Cannabinoids

    Sponsor: University Health Network, Toronto. Phase: NA. Conditions: Chronic Pain, Opioid Use, Cannabis

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07574294: Dual REmission in Moderate-to-SEvere asthMa and Nasal Polyps

    Sponsor: Azienda Ulss 2 Marca Trevigiana. Phase: . Conditions: Asthma, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07615283: Adebrelimab Combined With SHR2554 in Relapsed/Refractory PTCL and NK/T-Cell Lymphoma

    Sponsor: Sun Yat-sen University. Phase: PHASE1. Conditions: Relapsed or Refractory Peripheral T Cell Lymphoma, NKTCL

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06585683: Post-Trial Tuberculosis Case Finding: A Substudy of CoVPN 3008

    Sponsor: COVID-19 Prevention Network. Phase: . Conditions: Tuberculosis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07407894: iVS-1 Probiotic Intervention Targeting Biological Aging in Midlife Adults

    Sponsor: Synbiotic Health. Phase: NA. Conditions: Healthy Aging, Anti Aging

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT00690066: PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)

    Sponsor: Mesoblast, Inc.. Phase: PHASE2. Conditions: Type 1 Diabetes Mellitus, Type 1 Diabetes, Diabetes Mellitus, Insulin-Dependent, Juvenile Diabetes

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07322302: RESTORE: Comparing Two Approaches to Repeat TT Surgery Performed by Integrated Eye Care Workers (IECWs)

    Sponsor: University of North Carolina, Chapel Hill. Phase: NA. Conditions: Trachoma, Eye Diseases, Trichiasis

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07079631: A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

    Sponsor: BioNTech SE. Phase: PHASE1. Conditions: Metastatic Colorectal Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06420531: Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial

    Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Prematurity

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT04946253: SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care

    Sponsor: University of Pittsburgh. Phase: NA. Conditions: Child Behavior Problem, Attention Deficit and Disruptive Behavior Disorders

    full page →ctgov ↗
    ›TERMINATEDphase readoutNCT05175053: Early RRT in AKI After Cardiac Surgery

    Sponsor: Seoul National University Hospital. Phase: NA. Conditions: Acute Kidney Injury

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07512245: Assessment of Two Soft Tissue Augmentation Using Acellular Dermis Around Dental Implants

    Sponsor: University of Alabama at Birmingham. Phase: NA. Conditions: Acellular Dermal Matrix, Alveolar Mucosa

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT02583672: Role of Oxidative Stress and Inflammation in Type 1 Gaucher Disease (GD1)

    Sponsor: University of Minnesota. Phase: PHASE2. Conditions: Gaucher Disease Type 1

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT04804072: INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit

    Sponsor: HIV Prevention Trials Network. Phase: NA. Conditions: HIV Infections, Drug Use, Opioid Use, Opioid-use Disorder

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT01617395: Relating Genetic and Environmental Risk Scores to Multiple Sclerosis Susceptibility

    Sponsor: National Institute of Neurological Disorders and Stroke (NINDS). Phase: . Conditions: Multiple Sclerosis

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT04950439: Pyrophosphate and Arterial Calcification in Chronic Kidney Disease

    Sponsor: Centre Hospitalier Universitaire de Nice. Phase: NA. Conditions: Chronic Kidney Diseases

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07327177: BFR Rope Training in Male Volleyball Players

    Sponsor: Karabuk University. Phase: NA. Conditions: Volleyball, Performance, Power

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07050875: Clinical Investigation to Validate the Safety and Performance of the ABLE Exoskeleton Device for Individuals With Acquired Brain Injury in a Clinical Setting

    Sponsor: ABLE Human Motion S.L.. Phase: NA. Conditions: Acquired Brain Injury (Including Stroke)

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07346157: Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease

    Sponsor: Sabine Mueller, MD, PhD. Phase: PHASE1. Conditions: Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05134857: The Zonisamide and Reinforcement for Reducing Alcohol Use (ZARRA) Study

    Sponsor: Washington State University. Phase: PHASE2. Conditions: Alcohol Use Disorder (AUD)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT03972657: A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    Sponsor: Regeneron Pharmaceuticals. Phase: PHASE1. Conditions: Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Renal Cell Carcinoma (ccRCC)

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT06434012: Barts Endocarditis Research Registry

    Sponsor: Queen Mary University of London. Phase: . Conditions: Infective Endocarditis, Endocarditis, Endocarditis, Bacterial

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07020312: Brain-Computer Interface Visualization Training to Optimize Muscle Activation Following Orthopaedic Surgery

    Sponsor: Rush University Medical Center. Phase: PHASE2. Conditions: Anterior Cruciate Ligament Reconstruction, Total Hip Arthroplasty (THA), Total Knee Arthroplasty, Hip Arthroscopy

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07325630: Perioprative Study of IBI363 in Patients With MHC-II-Negative Locally Advanced Gastric Cancer

    Sponsor: Zhejiang Cancer Hospital. Phase: PHASE2. Conditions: IBI363 + Chemotherapy

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT00001230: Host Response to Infection and Treatment in Filarial Diseases

    Sponsor: National Institute of Allergy and Infectious Diseases (NIAID). Phase: . Conditions: Filariasis, Helminthiasis, Parasitic Infection, Mansonelliasis, Onchocerciasis

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06883630: A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC

    Sponsor: RemeGen Co., Ltd.. Phase: PHASE1. Conditions: Non-Small Cell Lung Cancer

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05865028: A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

    Sponsor: Elizabeth J Franzmann. Phase: PHASE2. Conditions: Oropharyngeal Dysplasia, Oral Cavity Dysplasia, Oral Carcinoma in Situ

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06439628: ARISE-A Chinese Real-world Study of Rimegepant for the Acute Treatment of Migraine

    Sponsor: Chinese PLA General Hospital. Phase: . Conditions: Migraine

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT06282328: HIV HOspital TEsting: Bringing the Hidden to Light in the Hospital Setting

    Sponsor: Castagna Antonella. Phase: . Conditions: Hiv, HIV Infections, AIDS

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07398365: Medical Phenotyping of NHS General Adult Psychiatry (GAP) Inpatients

    Sponsor: University of Edinburgh. Phase: . Conditions: Bipolar Affective Disorder, Schizophrenia Disorders, Depression Disorders, Personality Disorders

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07321067: Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes

    Sponsor: Ahmed Karam Helmy. Phase: . Conditions: Advanced Hepatocellular Carcinoma (HCC)

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT02868268: Neuroblastoma Precision Trial

    Sponsor: New Approaches to Neuroblastoma Therapy Consortium. Phase: . Conditions: Neuroblastoma

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT06766968: Prolonged Compression Following Foam Sclerotherapy

    Sponsor: Pirogov Russian National Research Medical University. Phase: NA. Conditions: Chronic Venous Disorder, Varicose Veins Leg

    full page →ctgov ↗
    ›NOT_YET_RECRUITINGphase readoutNCT07562568: SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS

    Sponsor: The First Affiliated Hospital of Soochow University. Phase: PHASE2. Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, MDS, Transplantation, Stem Cell, Conditioning Therapy, SHR2554, Azacytidine

    full page →ctgov ↗
    ›WITHDRAWNphase readoutNCT06720740: The RELIEF™ Ureteral Stent Randomized Controlled Trial

    Sponsor: University of California, San Diego. Phase: NA. Conditions: Kidney Stone

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT05919940: Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO )

    Sponsor: Technical University of Munich. Phase: NA. Conditions: ICU Acquired Weakness, Muscle Atrophy, Energy Malnutrition Protein, Quality of Life, Morphological and Microscopic Findings, Metabolic Disturbance

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07166289: Ultrasound Neuromodulation of Circuits and Negative Valence Systems in Treatment-Resistant Depression

    Sponsor: Laureate Institute for Brain Research, Inc.. Phase: NA. Conditions: Treatment-Resistant Depression

    full page →ctgov ↗
    ›RECRUITINGphase readoutNCT07343440: Trial on the Impact of Indirect Calorimetry-Guided Nutritional Support on Patient-Centered Outcomes in Critically Ill Patients - The OPTICal Study

    Sponsor: HEIDEGGER CP. Phase: NA. Conditions: Critical Illness, ICU

    full page →ctgov ↗
    ›COMPLETEDphase readoutNCT07024589: First-in-Human Trial of Oral AN2-502998

    Sponsor: AN2 Therapeutics, Inc. Phase: PHASE1. Conditions: Healthy Volunteers

    full page →ctgov ↗
    ›ACTIVE_NOT_RECRUITINGphase readoutNCT05047250: A Study of Atezolizumab in High PD-L1 Expression, Chemotherapy-Naïve Patients With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer

    Sponsor: Hoffmann-La Roche. Phase: PHASE3. Conditions: Non-Small Cell Lung Cancer

    full page →ctgov ↗
    ← prev
    page 94 of 110
    next →